The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.

REAL PATIENTS. REAL PICTURES.*

Select an image to see the OTEZLA difference.
Actual psoriasis patient with 49.7% reduction in PASI after 16 weeks on OTEZLA® (apremilast). Please see full Important Safety Information.
Baseline
Actual real-world OTEZLA patient. Property of Amgen Inc.
Actual psoriasis patient before treatment with OTEZLA® (apremilast). Please see full Important Safety Information.
PASI-49.7
Week 16: 49.7% reduction in PASI score
Actual real-world OTEZLA patient. Property of Amgen Inc.
Actual psoriasis patient with 52% decrease in PASI score after 16 weeks on OTEZLA® (apremilast). Please see full Important Safety Information.
Baseline
Actual OTEZLA patient from the ESTEEM 1 clinical trial.
Actual patient with psoriasis before treatment with OTEZLA® (apremilast)
PASI-52
Week 16 ESTEEM® 1: 52% reduction in PASI score
Actual OTEZLA patient from the ESTEEM 1 clinical trial.
Actual psoriasis patient with 69% decrease in PASI score after 16 weeks on OTEZLA® (apremilast). Please see full Important Safety Information.
Baseline
Actual OTEZLA patient from the ESTEEM 1 clinical trial.
Actual patient with psoriasis before treatment with OTEZLA® (apremilast). Please see full Important Safety Information.
PASI-69
Week 16 ESTEEM 1: 69% reduction in PASI score
Actual OTEZLA patient from the ESTEEM 1 clinical trial.
Actual patient with palmoplantar psoriasis after 16 weeks on OTEZLA® (apremilast). Please see full Important Safety Information.
Baseline
Actual OTEZLA patient from the ESTEEM 1 clinical trial.
Actual patient with palmoplantar psoriasis before treatment with OTEZLA® (apremilast). Please see full Important Safety Information.
PASI-70
Week 16: 70% reduction in PASI score
Actual OTEZLA patient from the ESTEEM 1 clinical trial.
Actual psoriasis patient with 70% decrease in PASI score after 16 weeks on OTEZLA® (apremilast). Please see full Important Safety Information.
Baseline
Actual OTEZLA patient from the ESTEEM 1 clinical trial.
Actual psoriasis patient before treatment with OTEZLA® (apremilast). Please see full Important Safety Information.
PASI-70
Week 16: 70% reduction in PASI score
Actual OTEZLA patient from the ESTEEM 1 clinical trial.
Actual patient with psoriasis who achieved a 75% decrease in PASI after 16 weeks on OTEZLA®. Please see full Important Safety Information.
Baseline
Actual real-world OTEZLA patient. Property of Amgen Inc.
Actual patient with psoriasis before treatment with OTEZLA® (apremilast). Please see full Important Safety Information.
PASI-75
Week 16: 75% reduction in PASI score
Actual real-world OTEZLA patient. Property of Amgen Inc.
Actual psoriasis patient with 76.5% decrease in PASI after 16 weeks on OTEZLA® (apremilast). Please see full Important Safety Information.
Baseline
Actual real-world OTEZLA patient. Property of Amgen Inc.
Actual psoriasis patient before treatment with OTEZLA® (apremilast). Please see full Important Safety Information.
PASI-76.5
Week 16: 76.5% reduction in PASI score
Actual real-world OTEZLA patient. Property of Amgen Inc.
Actual psoriasis patient who had a 76.5% decrease in PASI score after 16 weeks on OTEZLA® (apremilast). Please see full Important Safety Information.
Baseline
Actual real-world OTEZLA patient. Property of Amgen Inc.
Actual psoriasis patient before treatment with OTEZLA® (apremilast). Please see full Important Safety Information.
PASI-76.5
Week 16: 76.5% reduction in PASI score
Actual real-world OTEZLA patient. Property of Amgen Inc.
Actual psoriasis patient who had a 76.5% decrease in PASI score after 16 weeks on OTEZLA® (apremilast). Please see full Important Safety Information.
Baseline
Actual real-world OTEZLA patient. Property of Amgen Inc.
Actual psoriasis patient before treatment with OTEZLA® (apremilast). Please see full Important Safety Information.
PASI-76.5
Week 16: 76.5% reduction in PASI score
Actual real-world OTEZLA patient. Property of Amgen Inc.
Actual psoriasis patient with 80% reduction in PASI score after 16 weeks on OTEZLA® (apremilast). Please see full Important Safety Information.
Baseline
Actual real-world OTEZLA patient. Property of Amgen Inc.
Actual patient with psoriasis before treatment with OTEZLA® (apremilast). Please see full Important Safety Information.
PASI-80
Week 16: 80% reduction in PASI score
Actual real-world OTEZLA patient. Property of Amgen Inc.
Actual psoriasis patient with 80% reduction in PASI score after 16 weeks on OTEZLA® (apremilast). Please see full Important Safety Information.
Baseline
Actual real-world OTEZLA patient. Property of Amgen Inc.
Actual psoriasis patient before treatment with OTEZLA® (apremilast). Please see full Important Safety Information.
PASI-80
Week 16: 80% reduction in PASI score
Actual real-world OTEZLA patient. Property of Amgen Inc.
Actual patient with skin plaques who achieved an 80% decrease in PASI after 16 weeks on OTEZLA® (apremilast). Please see full Important Safety Information.
Baseline
Actual real-world OTEZLA patient. Property of Amgen Inc.
Actual patient with skin plaque before treatment with OTEZLA® (apremilast). Please see full Important Safety Information.
PASI-80
Week 16: 80% reduction in PASI score
Actual real-world OTEZLA patient. Property of Amgen Inc.
Actual psoriasis patient with 85% reduction in PASI after 16 weeks on OTEZLA® (apremilast). Please see full Important Safety Information.
Baseline
Actual OTEZLA patient from the ESTEEM 1 clinical trial.
Actual psoriasis patient before treatment with OTEZLA® (apremilast). Please see full Important Safety Information.
PASI-85
Week 16 ESTEEM 1: 85% reduction in PASI score
Actual OTEZLA patient from the ESTEEM 1 clinical trial.
Actual patient whose scalp psoriasis cleared (ScPGA = 0) after 16 weeks of OTEZLA® (apremilast) treatment. Please see full Important Safety Information.
Baseline
Actual OTEZLA patient from the ESTEEM 1 clinical trial.
Actual patient with scalp psoriasis before treatment with OTEZLA® (apremilast). Please see full Important Safety Information.
ScPGA-0
Week 16 ESTEEM 1: ScPGA-0 result
Actual OTEZLA patient from the ESTEEM 1 clinical trial.
*Individual results may vary.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 54 countries*
  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Singapore

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Kuwait

  • Taiwan

  • UAE

  • South Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil

  • Malaysia

  • Oman

  • Saudi Arabia

On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).

Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.

For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.